Giessler Goetz A, Gades Naomi M, Friedrich Patricia F, Bishop Allen T
Department of Orthopedic Surgery, Microvascular Research Laboratory, Mayo Clinic, Rochester, MN 55905, USA.
Exp Clin Transplant. 2007 Jun;5(1):590-5.
Tacrolimus is an effective immunosuppressant, safely administered in clinical practice by monitoring blood levels. In experimental transplants, many dosage regimens have been reported, often without such determinations. Anorexia and organ toxicity commonly occur. We report the toxic effects of tacrolimus in rabbits receiving intramuscular injections (1 mg/kg/d) and the subsequent dosage modifications that resulted in improved animal survival without toxic effects.
To obtain nontoxic drug concentrations in the blood, 3 dosage regimens were required. Drug concentrations were targeted using therapeutic human values as a guide (range, 5-20 ng/mL). First, a group of 12 Dutch-Belted rabbits received vascularized femoral allografts and were treated with intramuscular dosages of tacrolimus (1 mg/kg/d) for 14 days. Subsequently, dosage reductions in 10 more rabbits, to 0.2 mg/kg/d for 14 days, were necessary. Finally, another group of 20 rabbits was treated with 0.08 mg/kg for 3 days, and then every other day thereafter. Weight loss > 30%, cardiopulmonary failure, and/or creatinine levels > 221 micromol/L were the criteria approved by our local Institutional Animal Care and Use Committee for euthanizing the animals. Treated animals were compared with 20 nonimmunosuppressed controls that underwent the same operation.
At an intramuscular dosage of 1 mg/kg/d, the mean tacrolimus blood level was 90.7 ng/mL. Ten of the 12 animals in the original group died or required euthanasia. At necropsy, renal failure, cardiac abnormalities, and pulmonary edema were found. The tacrolimus dosage of 0.2 mg/kg/d produced a mean tacrolimus blood level of 17.6 ng/mL; however, 8 of the subsequent 10 rabbits died when given this dosage. Ultimately, the 0.08 mg/kg regimen in 20 rabbits permitted survival of 18 animals with a mean tacrolimus blood level of 6.8 ng/mL. None of 20 nonimmunosuppressed controls died after surgery.
For successful immunosuppression, Dutch-Belted rabbits require intramuscular tacrolimus dosages lower those required in other rabbit breeds. This has not been reported previously. The 0.08 mg/kg/d dosage combined with intermittent drug level monitoring permits survival without significant complications.
他克莫司是一种有效的免疫抑制剂,在临床实践中通过监测血药浓度安全给药。在实验性移植中,已报道了许多给药方案,通常未进行此类测定。厌食和器官毒性常见。我们报告了接受肌肉注射(1mg/kg/d)的兔子中他克莫司的毒性作用以及随后的剂量调整,这些调整提高了动物存活率且无毒性作用。
为了在血液中获得无毒药物浓度,需要3种给药方案。以治疗性人体值为指导(范围为5 - 20ng/mL)来设定药物浓度目标。首先,一组12只荷兰带兔接受带血管的股异体移植,并接受他克莫司肌肉注射剂量(1mg/kg/d)治疗14天。随后,另外10只兔子的剂量减至0.2mg/kg/d,持续14天。最后,另一组20只兔子先以0.08mg/kg治疗3天,然后此后隔天给药。体重减轻>30%、心肺衰竭和/或肌酐水平>221微摩尔/升是我们当地机构动物护理和使用委员会批准的对动物实施安乐死的标准。将治疗的动物与20只接受相同手术的未免疫抑制对照进行比较。
肌肉注射剂量为1mg/kg/d时,他克莫司的平均血药浓度为90.7ng/mL。原组12只动物中有10只死亡或需要安乐死。尸检发现肾衰竭、心脏异常和肺水肿。0.2mg/kg/d的他克莫司剂量产生的平均血药浓度为17.6ng/mL;然而,随后10只兔子中有8只接受此剂量时死亡。最终,20只兔子采用0.08mg/kg方案,18只存活,他克莫司平均血药浓度为6.8ng/mL。20只未免疫抑制对照术后均未死亡。
为成功进行免疫抑制,荷兰带兔所需的他克莫司肌肉注射剂量低于其他兔种。此前未见此报道。0.08mg/kg/d的剂量与间歇性药物浓度监测相结合可使动物存活且无明显并发症。